Senzo, a Philadelphia, PA-based life sciences company, raised additional $1.9M in Equity funding.
The round was led by BioAdvance and Wellness Coaches.
Led by CEO Jeremy Stackawitz, Senzo is an in vitro diagnostics company developing mobile, point-of-care and self-testing products and devices with the ability to accurately conduct testing where healthcare professionals and patients need it most.
The company intends to use the funds to complete validation, execute clinical trials, secure FDA EUA authorization, and scale manufacturing for the ALF COVID-19 test, as well as to advance R&D for new Flu A/B, RSV, Tuberculosis, HIV, Hepatitis-C, and Strep tests.
Senzo plans to complete ALF COVID-19 clinical trials and secure FDA EUA regulatory approval in 1H 2023, with tests commercially available in the 2H 2023.
FinSMEs
14/12/2022